Human Genome Sued by Shareholder Over $3 Billion Glaxo Deal

Human Genome Science Inc., being taken-over by lupus-drug partner GlaxoSmithKline Plc for about $3 billion, was sued by a shareholder claiming the offer shortchanges investors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.